MedTrace Logo

Polymorphisms of Interleukins, Glypican, and Human Leukocyte Antigen Genes and Treatment Response in Multiple Sclerosis.

NCT02769767 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 500

Last updated 2016-05-12

No results posted yet for this study

Summary

HLA-DRB1 \* Gene and some genes involved in inflammation and immunity (IL-7R, GPC5, CTSS) have been linked to risk of MS and the response to treatment with immunomodulators. This research aims to estimate the risk that confers some variations in the sequence of these genes.

Conditions

  • Multiple Sclerosis, Relapsing-Remitting

Interventions

GENETIC

Polymorphism of Interleukins, Glypican, and Human Leukocyte Antigen Genes.

The frequencies of the polymorphic variants in subjects with MS and healthy subjects were evaluated. Also in subjects with MS, the response to treatment with the number of relapses and EDSS was assessed; to compare the allele frequencies of SNPs of Interleukins, Glypican, and Human Leukocyte Antigen Genes, between responders and no responders MS patients.

Sponsors & Collaborators

  • Instituto Mexicano del Seguro Social

    collaborator OTHER_GOV

  • University of Guadalajara

    collaborator OTHER

  • Instituto Jalisciense de Cancerologia

    lead OTHER_GOV

Principal Investigators

  • JOSE A. CRUZ RAMOS, PhD · Instituto Jalisciense de Cancerología

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2012-08-31
Primary Completion
2016-12-31
Completion
2016-12-31

Countries

  • Mexico

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02769767 on ClinicalTrials.gov